Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD
Empagliflozin Indicated for HFpEF
Waist Circumference and Early Detection of Diabetes
An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
182% Increase of New-Onset T2D in Youth During the COVID-19 Pandemic
Considerations for Making and Achieving Individualized A1c Goals
Letter from the Editor
We keep seeing more evidence on the value of GLP-1 agonists and SGLT-2 inhibitors on protection and improvement in cardio and renal outcomes. This week when Steve and I looked at features from our interns to publish, we selected multiple articles that show how these classes of drugs are making a difference both for diabetes and the comorbidities associated with diabetes.
One of the features shared by Kornelia Ilias, Pharm.D. Candidate, Creighton University School of Pharmacy and Health Professions, adds another class of drugs to the list, and fortunately for us the first in the class also has a GLP-1 agonist effect.
Check out Dr. Ilias’ Laterpay feature to learn what a GIP is, and which new medication has the dual effect.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.
The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).
Measuring waist circumference could provide an inexpensive way to assess risk of developing insulin resistance.
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.
Worse clinical outcomes are seen during the pandemic for non-Hispanic Black youth with T2D.
A1c goals are not a one-size-fits-all; here are some factors you might want to think about to help patients meet their target A1c goals.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:
Andy Dao, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022
Emmanuella Louissaint, PharmD candidate, LECOM College of Pharmacy
Trina Maglalang RPh, 2022 PharmD Candidate, University of Colorado
Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com